ABSTRACT
Background Different SARS-CoV-2 variants can differentially affect the prevalence of Post Covid-19 Condition (PCC). This prospective study assesses prevalence and severity of symptoms three months after an Omicron infection, compared to Delta, test-negative and population controls. This study also assesses symptomology after reinfection and breakthrough infections.
Methods After a positive SARS-CoV-2 test, cases were classified as Omicron or Delta based on ≥ 85% surveillance prevalence. Population controls were representatively invited and symptomatic test-negative controls enrolled after a negative SARS-CoV-2 test. Three months after enrolment, participants indicated point prevalence for 41 symptoms and severity of four symptoms. Permutation tests identified significantly elevated symptoms in cases compared to controls. PCC prevalence was estimated as the difference in prevalence of at least one elevated symptom in cases compared to population controls.
Findings At three months follow-up, five symptoms and severe dyspnea were significantly elevated in Omicron cases (n = 4138) compared to test-negative (n= 1672) and population controls (n= 2762). PCC prevalence was 10·4% for Omicron cases and 17·7% for Delta cases (n = 6855). Prevalence of severe fatigue and dyspnea were higher in reinfected compared to primary infected Omicron cases, while severity of symptoms did not significantly differ between Omicron cases with a booster or primary vaccination course.
Interpretation Three months after Omicron, prevalence of PCC is 41% lower than after Delta. Reinfection seems associated with more prevalent severe long-term symptoms compared to a first infection. A booster prior to infection does not seem to improve the outcome of long-term symptoms.
Funding The study is executed by the National Institute for Public Health and the Environment by order of the Ministry of Health, Welfare and Sport.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://bmjopen.bmj.com/content/12/7/e062439.long
Funding Statement
The study is executed by the National Institute for Public Health by order of the Ministry of Health. The study is not the result of a competitive grant. The Dutch Ministry of Health, Welfare and Sport does not have a role in the design of this study, its execution, analyses and interpretation of results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Utrecht Medical Ethics Committee of NedMec gave ethical approval for this work (protocol number 21-124/C)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Supporting clinical documents including the study protocol and statistical analysis plan will be available immediately following publication of this Article for at least 1 year. Researchers who provide a methodologically sound proposal will within the applicable privacy legislation be allowed to access to the de-identified individual participant data that underlie the results reported in this article. Proposals should be sent to the corresponding author. These proposals will be reviewed and approved by the investigators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.
List of abbreviations
- CIS
- Checklist Individual Strength
- CFQ
- Cognitive Failure Questionnaire
- mMRC
- Modified Medical Research Council dyspnea scale
- PCC
- Post-Covid-19 Condition
- PCR
- polymerase chain reaction
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- SF-36
- SF-36 item Health Survey
- TiC-P
- Treatment Inventory of Costs in Patients with psychiatric disorders
